For enquiries, please contact:
Notes to Editors
About GlycoSeLect Ltd
GlycoSeLect Ltd is an early-stage BioTechnology company developing proprietary next-generation, highly specific and cost-efficient tools for the analysis, characterisation and purification of biotherapeutics. Spun-out from Dublin City University in 2013, GlycoSeLect specialises in the development of RPLs; enhanced glycoselective bioaffinity proteins that enable efficient detection, analysis and selective isolation of glycosylated biomolecules. GlycoSeLect’s current family of RPLs target a range of galactose and mannose glycoprofiles and are associated with market leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness.
GlycoSeLect UK Ltd was established in 2015 to support further development, provide wider geographic reach and drive commercialisation
About Centre for Process Innovation
The Centre for Process Innovation is a UK-based technology innovation centre and part of the High Value Manufacturing Catapult. We use applied knowledge in science and engineering combined with state of the art development facilities to enable our clients to develop, prove, prototype and scale up the next generation of products and processes.
Our open innovation model enables clients to develop products and prove processes with minimal risk. We provide assets and expertise so our customers can demonstrate the process before investing substantial amounts of money in capital equipment and training. New products and processes can be shown to be feasible; on paper, in the lab and in the plant before being manufactured at an industrial scale.
By utilising our proven assets and expertise companies can take their products and processes to market faster. There is no down time in production as all of the process development is completed offsite and our technology transfer and engineering teams can help companies to transfer the product or process into full scale production at speed.
Robert Dunne, CEO
Tel: + 353 (0 ) 87 790 2652
Dr. Natasha Lethbridge
Tel: +44 (0) 1325 376 813
CPI has contributed its expertise in biotherapeutics to support an Innovate UK funded project focused on developing and integrating novel recombinant prokaryotic lectins (RPLs) into a biosensor-based platform.
CPI Supports GlycoSeLect to Develop High Throughput Glycan Analysis Platform for Biotherapeutics